Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

Filter
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:

*Includes seizure clusters and acute or prolonged seizures

146 result(s)

phase 3

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase 3 randomized, double-blind, placebo-controlled trial

Victor Biton, Samuel F Berkovic, Bassel Abou-Khalil et al.  November 08, 2013
phase 3

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial

Philippe Ryvlin, Konrad J Werhahn, Barbara Blaszczyk et al.  October 28, 2013
phase 3

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase 3, double-blind, randomized, placebo-controlled, flexible-dose trial

Patrick Kwan, Eugen Trinka, Wim Van Paesschen et al.  October 03, 2013
phase 2

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase 2b, randomized, controlled trial

Wim Van Paesschen, Edouard Hirsch, Martin Johnson et al.  July 19, 2012
pre clinical

BRIVIACT® (brivaracetam) CV

View

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse, and human brain: relationship to anti-convulsant properties

Michel Gillard, Bruno Fuks, Karine Leclercq et al.  May 08, 2011
phase 2

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial 

J A French, C Costantini, A Brodsky et al.  June 30, 2010